Bayer has once again found itself at the center of high-profile news related to its herbicide Roundup. Last Friday, the company announced that it had refiled a request with the US Supreme Court to sharply limit litigation claims alleging that Roundup causes cancer, measures aimed at preventing potentially multi-billion-dollar losses. In its statement published on the "opens a new tab" platform, Bayer insists that consumers should not have the right to sue under state law for failing to warn that Roundup increases the risk of cancer. This position is supported by the fact that the Environmental Protection Agency (EPA) in the United States has not identified such risks, nor does it mandate additional warnings beyond those approved on the official EPA label.

Bayer has announced an ambitious plan to launch two groundbreaking drugs this year, each with the potential to generate annual revenues of at least one billion dollars. This strategic move is designed to reinforce the company’s pharmaceutical division amid a backdrop of high debt levels. Known for its robust commitment to healthcare and agricultural products, Bayer’s initiative reflects an adaptive response to evolving global market demands and competitive pressures within the pharmaceutical industry.